INTS

Intensity Therapeutics, Inc. (NASDAQ:INTS) is a clinical-stage biotechnology company founded in 2012 and headquartered in Westport, Connecticut. The company went public in June 2023 and focuses on developing innovative cancer treatments for solid tumors. Intensity Therapeutics operates in the oncology drug development space, with its lead product candidate currently in Phase 2 clinical trials for treating various refractory solid tumors including pancreatic, colon, bile duct, and other challenging cancers.